Daiichi Sankyo

The state of the hunt:

Pfizer and BioNTech plan to seek authorization of their vaccine for adolescents age 12-15 after promising Phase 3 results.
  J&J agreed to supply up to 400 million doses of Janssen’s jab to the African Union.
  Serum Institute of India launched clinical trials of its version of the Novavax vaccine candidate.

 

Vaccines


Approved or authorized vaccines
   
New data show lower efficacy for Pfizer/BioNTech: The…

The state of the hunt:

The European Union and India made new moves to curtail vaccine exports.
  COVAX warned of delivery delays.
  Pfizer and BioNTech launched a pediatric trial of their vaccine in children as young as 6 months.

 

Vaccines


Approved or authorized vaccines
   
New data, new questions for AstraZeneca: If AstraZeneca thought higher-than-expected efficacy results this week from the U.S.-based Phase 3 trial of AZD1222 would…

The state of the hunt:

Novavax’s protein-based vaccine candidate demonstrated 89.3% efficacy in a UK Phase 3 trial.
  J&J/Janssen’s single-dose vaccine was 66% effective against moderate to severe disease in Phase 3.
  Vaccines from J&J, Moderna, Novavax and Pfizer/BioNTech appear less effective against the SARS-CoV-2 variant first identified in South Africa.

 

Vaccines


Approved or authorized vaccines

AstraZeneca’s vaccine…

The state of the hunt:

Novavax’s protein-based vaccine candidate demonstrated 89.3% efficacy in a UK Phase 3 trial.
  J&J/Janssen’s single-dose vaccine was 66% effective against moderate to severe disease in Phase 3.
  Vaccines from J&J, Moderna, Novavax and Pfizer/BioNTech appear less effective against the SARS-CoV-2 variant first identified in South Africa.

 

Vaccines


Approved or authorized vaccines

AstraZeneca/Oxford’s…

The state of the hunt:

AstraZeneca commenced a U.S. Phase 3 trial of its AZD1222 vaccine candidate.
  Sanofi/GSK launched the first human trials of their investigational adjuvanted vaccine.
  Germany, Japan and Norway joined the COVAX Facility, which now has commitments from 78 upper- and upper-middle-income countries.

 

Vaccines

Phase 3 candidates:
 
AstraZeneca’s AZD1222 vaccine entered a United States-based Phase 3 trial targeting 30,000…

Takeda announced Monday that it would sell its Japanese consumer healthcare business for $2.3 billion to U.S. buyout fund Blackstone Group. The Japanese company has been selling noncore assets worldwide as it seeks to refocus its business and reduce debt following a $59 billion acquisition of Britain’s Shire last year.

Financial Times reported that Blackstone hopes the move will “spur a series of similar asset sales”—allowing it to ultimately create an over-the-counter (OTC) drug giant…

Xiamen Innovax announced last week that it is licensing its rotavirus technology to Sanofi to develop and commercialize outside China. GBI Source reported that Sanofi will pay the Chinese biotech $68 million (including milestones) for the rights, plus 1-2% royalties on net sales.

Meanwhile, Sanofi quietly indicated in its July 29 earnings press release that it will drop a much-delayed deal with Daiichi Sankyo to develop a pediatric polio-containing pentavalent shot for Japan.

AstraZeneca announced this week that it will pay up to $6 billion in a development and commercialization deal with Daiichi Sankyo for DS-1062, the Japanese company’s antibody-drug conjugate (ADC) for non-small cell lung cancer and triple-negative breast cancer, currently in Phase 1. According to the press release, AstraZeneca will pay Daiichi Sankyo $1 billion upfront and up to $5 billion in additional regulatory and sales milestones for rights outside Japan.
 
The two companies…

The state of the hunt:

China sent another inactivated candidate to Phase 2—its fourth vaccine of that type to move beyond Phase 1 trials.
  CEPI has identified manufacturing capacity for 4 billion vaccine doses.
  The WHO-led Access to COVID-19 Tools (ACT) Accelerator is seeking almost $28 billion in additional funds.

 

Vaccines

Clinical trials:

Another Chinese candidate in Phase 2: An inactivated vaccine from the Chinese Academy of Medical…


The state of the hunt: 

Moderna expects to begin Phase 3 trials of its mRNA-1273 vaccine candidate next month. J&J moved up the targeted launch of Phase 1/2a trials of its Covid-19 vaccine candidate from September to July. Sinovac teamed up with Instituto Butantan, which will sponsor Brazilian Phase 3 trials of the Chinese company’s inactivated vaccine candidate.

 

Vaccines

Existing candidates:
 
Moderna announced plans yesterday to commence Phase…